George Perry (University of Texas at San Antonio [UTSA], San Antonio, TX), a valued member of our editorial board for US Neurology, discusses therapeutic targets in Alzheimer’s disease with a particular focus on the role of oxidative stress in the underlying pathophysiology of the disease.
Questions
1. Why do you think so many Alzheimer’s disease (AD) therapies have failed in phase III clinical studies? (0:09)
2. What are the most promising alternative therapeutic targets under investigation? (0:54)
3. What is the role of oxidative stress in the pathophysiology of AD? (1:49)
4. What is the main intracellular source of oxidative stress in AD? (2:36)
5. How can oxidative stress and mitochondria be targeted therapeutically? (3:17)
Speaker disclosure: George Perry serves as an advisor for Investicure and Phoenix Biotech, and is a board member for Neurotez and Neurotrope.
Filmed during a video call with Editorial Board member George Perry from his office at the University of Texas at San Antonio (UTSA), San Antonio, TX, US, July 2018.
